What podcasts say about Bilal Kharouni
Every statement, with the speaker, the exact quote and the moment it was said.
What Bilal Kharouni has said on podcasts
37 statements · 25 positive · 8 negative · 1 mixed · 3 neutral
EK Labs generates high-resolution, low-cost epigenetic data for drug development.
“we generate high resolution and low cost epigenetic data for drug development”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 4:27
Japan has produced some of the strongest innovation in regenerative medicine.
“Some of the best innovation have been created here in Japan.”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 5:19
Epigenetic methylation signals change with aging and therapeutic responses.
“it changes with aging, it changes with therapeutic responses”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 6:32
EK Labs reads DNA methylation signals at unusually high resolution and low cost.
“we have a way to read the signals in a way that is incredibly high resolution and at an incredible low cost”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 6:50
EK Labs works with cohorts ranging from hundreds to thousands of participants.
“we're lucky enough to work with very large cohorts with hundreds and sometimes thousands of participants”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 7:37
EK Labs tests stem-cell batches for manufacturing quality control.
“we also run tests on different stem cell batches for the manufacturing quality control”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 8:09
Data generation is the main competitive moat in AI for biology.
“in AI for biology, the moat is in data generation”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 8:57
AI models cannot compensate for missing biological data.
“you cannot really model your way out from a data set that isn't there”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 9:07
Virtual-cell organisms will be the next frontier of AI modeling.
“my prediction is that the next frontier for AI modeling will be virtual cell organism”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 9:43
Drugs developed using virtual-cell models will be groundbreaking.
“the new drug that will hit the markets will be absolutely groundbreaking”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 10:00
Longevity treatments currently lack consensus on what works for patients.
“right now there's not really a consensus of what would actually work for the, for the patients”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 12:14
A first clinical trial has tested a drug that might reverse aging.
“we've had the first clinical trial for a drug that might actually reverse aging”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 12:35
Stem-cell therapies can be highly effective, depending on the clinical indication.
“Stem cells can be in cell therapies in general can be absolutely amazing. But it really depends on what is the clinical indication that you're going for.”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 14:01
Unsupervised off-label longevity treatments can be dangerous.
“doing things off menu and with your own will without like a framework and someone following you, I think can be dangerous”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 14:19
Cell therapies can be part of medical care when used for clinical indications.
“if you look at a clinical indication, I 100% believe that can be part of medical journey”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 15:43
Right-to-try laws should allow terminally ill patients access to unapproved cell or gene therapies.
“it would be the right for if you have for example an ineral disease, you have the right to try a therapy like a cell therapy, a gene therapy that haven't been approved yet”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 17:17
Deliberately infecting healthy people for medical research crosses Bilal Kharouni’s ethical boundary.
“the ethical question of getting someone sick, even if you can advance the research, is maybe like a border that I would not cross”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 20:07
The FDA increasingly intends to fast-track cell and gene therapies.
“you have more and more intention from the FDA to fast track cell therapy and gen therapy”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 24:42
Japan’s Regenerative Medicine Law fast-tracks cell and gene therapies.
“the Regenerative Medicine Law act was enacted and that's really fast track cell therapies and gene therapies in Japan”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 25:06
EK Labs locates its research and development laboratory in Okinawa.
“we have located all of our R in Okinawa, so we have our own lab bench”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 27:10
Japanese regional banks provide loans to biotech startups.
“regional banks are risk takers. They do give loans to biotech startups”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 31:12
Japanese early-stage startup funding is sometimes slow and involves small checks.
“the early stage funding is still sometimes slow and with small checks”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 32:49
Running a startup in Japan is less expensive than running one in San Francisco.
“definitely less expensive than running a startup in San Francisco”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 33:50
Japanese startups can accomplish substantial results after raising relatively little capital.
“what a Japanese startup that's raised 200k they were able to accomplish”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 34:18
Japan wants to encourage acquisitions as startup exits, which could improve the ecosystem.
“they want to encourage me to acquisition as exits and I Think that would be really healthy”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 36:30
EK Labs terminated its longevity-clinic services business.
“we decided to completely terminate this business”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 41:04
EK Labs believes data generation will create the greatest company value.
“what will really make the value of the company explode, which is a race for data generation”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 41:13
Biological age estimates benchmark biomarkers against cohorts of similar-aged people.
“it's really finding a biomarker and then just looking how you benchmark”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 45:56
Optimizing wearable biomarkers can become disconnected from actual health.
“you're trying to optimize for biomarkers that can be disconnected from your actual health”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 46:14
Aging biomarkers can help design clinical trials and support drug discovery.
“biomarkers of aging for drug development, then you can find some value”
Open the episode · Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315Listen at 46:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.